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Early glandular neoplasia of the lung
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Abstract
Although bronchogenic carcinomas progress through a very well defined sequence of
metaplasia, dysplasia and carcinoma in situ, very little is known about the early progression
of glandular neoplasms of the lung. In particular, the early precursor lesion from which fully
malignant adenocarcinomas arise has effectively eluded recognition, at least until recently.
Several lines of evidence now implicate atypical adenomatous hyperplasia (AAH) as an
initial morphologic stage in multistep lung tumorigenesis. Despite its small size, AAH can
be appreciated at the light microscopic level and characterized at the molecular genetic
level. Indeed, the genetic characterization of AAH promises to further our understanding of
lung cancer development and might facilitate the design of novel strategies for early
detection of lung cancer.
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Introduction
Lung cancer is the leading cause of cancer death in the
industrialized world [1]. A dismally low cure rate largely
reflects the propensity of lung cancer to present as clinically
advanced tumors: most lung cancers are discovered late
during their clinical course, by which time the options for
effective therapeutic intervention are limited. Of these lung
cancers, adenocarcinoma is now the most common
subtype [2]. This subtype is particularly notorious for
eluding early detection. Even vigilant screening of sputum
samples for morphologic evidence of early glandular neopla-
sia in individuals at risk is ineffective in curbing mortality
rates [3]. Adenocarcinomas of the lung tend to arise periph-
erally, and malignant cells are not shed into the sputum until
these tumors have developed into sizeable and frankly inva-
sive cancers. The inability to detect early glandular neopla-
sia has not only frustrated efforts to treat patients effectively
but has also hampered attempts to address fundamental
questions about how normal alveolar cells become malig-
nant. Understanding the early steps of lung tumorigenesis at
the molecular genetic level might facilitate the development
of more effective strategies for the prevention, early diagno-
sis, and treatment of lung cancer.
Historical concepts
Unlike central bronchogenic tumors, in which unwavering
progression through the metaplasia–dysplasia–carcinoma
in situ sequence has long been recognized, the morphologicRespiratory Research    Vol 1 No 3 Westra
progression of early glandular neoplasia has been
shrouded in mystery. Earliest attempts to explain the origin
of lung adenocarcinoma date back at least to the observa-
tion by Friedrich in 1939 that peripheral lung cancers often
coincide with subpleural anthrocotic scars [4]. According
to the ‘scar cancer’ concept, scar formation acts as an
inciting focus for epithelial regeneration, proliferation, and
ultimate neoplastic transformation. Over time, this concept
has fallen into disrepute. Studies indicate that tumor-asso-
ciated scarring, in most instances, seems to be a conse-
quence of invasive tumor growth rather than a pre-existing
soil in which neoplasms germinate and grow [5–8].
The inability to understand the precursor lesion of glandu-
lar neoplasia has perpetuated the desperate concept of
de novo carcinoma, a vague notion that fully malignant
lung adenocarcinoma materializes spontaneously in the
absence of a precursor lesion. The concept of de novo
carcinoma has now been rendered obsolete by the con-
temporary model of tumorigenesis. Simply stated, the
accumulation of specific genetic alterations drives tumori-
genesis forward through a sequential progression of well-
defined morphologic steps [9]. The current model of
tumorigenesis stipulates the presence, no matter how
transient and elusive, of a glandular precursor to periph-
eral lung adenocarcinoma.
In 1988, Miller et al [10•] observed that nearly 10% of all
lungs resected for adenocarcinomas also harbored minute
discrete foci of cytologically atypical bronchiolalveolar
cells. In light of the cytologic atypia and the strong associ-
ation with lung adenocarcinomas, they postulated that
these small lesions represented the elusive precursor
lesion: a glandular carcinoma in situ possessing the
potential to evolve into a frankly malignant adenocarci-
noma. These atypical proliferations are now commonly
referred to as atypical adenomatous hyperplasia (AAH) or
atypical alveolar hyperplasia.
Atypical adenomatous hyperplasia: a
morphologic manifestation of early glandular
neoplasia
On meticulous inspection, AAH can sometimes be seen
with the naked eye as tan-to-gray firm nodules that range
in size from about 1 to 7mm (Fig. 1). By light microscopy,
they are characterized by the proliferation of cuboidal to
columnar epithelial cells with various degrees of cytologic
atypia (Fig. 2). These cells line intact, albeit thickened,
alveolar septa [11]. In contrast to reactive pneumocyte
hyperplasia, they are not associated with significant
inflammation and fibrosis of the surrounding lung
parenchyma; unlike most lung adenocarcinomas they do
not demonstrate infiltrative growth with disruption of
normal lung architecture. The range of cytoarchitectural
atypia falls along a spectrum of increasing severity. Low-
grade lesions are characterized by a single layer of round
to cuboidal cells with low cellular density, small cell size,
and minimal variation in nuclear size, shape, and chro-
maticity. In low-grade lesions there is minimal thickening of
the alveolar septum. With progressive atypia, AAH demon-
strates a higher cellular density with stratification of the
epithelial cells, more significant cytological atypia, and
more extensive fibrosis and thickening of the alveolar septa.
Because of problems with reproducibility, grading of AAH
is not routinely employed [12]. Moreover, the precise point
at which a high-grade AAH becomes a bronchioloalveolar
carcinoma remains to be defined satisfactorily.
Figure 1
Cut surface of lung showing a 4 mm nodule of atypical adenomatous
hyperplasia (magnification ×14).
Figure 2
Histologic section of an atypical adenomatous hyperplasia. (A) The
lesion shows preservation of normal lung architecture and is
surrounded by normal lung parenchyma. (B) Higher magnification
shows a single layer of cuboidal cells with cytologic atypia lines septae
that are mildly thickened.c
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Several lines of evidence have bolstered the proposition
that AAH is a precursor lesion from which lung adenocar-
cinomas arise. First, there is guilt by association: lungs
with adenocarcinomas often also harbor one or several
AAHs [10•,11,13, 14••–16]. Indeed, foci of AAH are found
in as many as 25% of lungs resected for primary adeno-
carcinoma [15] but in only 2% of post-mortem lungs from
patients without lung neoplasms [17]. Second, AAH is
usually encountered in lungs of patients who smoke
tobacco, a known initiator and promoter of lung carcino-
genesis [11,14••]. Third, AAH seems to bridge the gap
between reactive pneumocyte hyperplasia and well-differ-
entiated adenocarcinoma. AAH occupies some middle
ground in terms of mean nuclear size [18,19•,20], DNA
content [18,21,22], cell proliferation [22–25••], expression
of carcinoembryonic antigen [19•,26], and altered expres-
sion of important regulators of the cell cycle such as the
p53 protein product [19•,25••,27•,28] and the p27/Kip1
protein product [29].
Molecular genetic characterization of AAH
Despite mounting evidence, the true nature of AAH could
not be unequivocally established in the absence of mole-
cular genetic characterization. On morphologic grounds
alone, AAH was difficult to distinguish from a reactive
proliferation. Reactive pneumocyte hyperplasia can be
seen in response to various types of lung injury, and the
degree of reactive cytologic atypia can even exceed the
neoplastic atypia of some lung cancers. At the other
extreme, AAH could not be readily distinguished from an
advanced pattern of tumor spread such as creeping
extension from an adjacent carcinoma or metastatic
implantation from a non-contiguous carcinoma. For
example, the advancing edge of non-mucinous bronchi-
oloalveolar carcinomas is morphologically indistinguish-
able from AAH, and the pattern of multiple small nodules
due to metastatic implantation is a characteristic feature
of mucinous bronchioloalveolar carcinomas. Thus, the
initial role of molecular genetic analysis in the evaluation
of AAH was to establish its nature as an early glandular
neoplasm in distinction to a reactive proliferation or some
form of advanced tumor spread.
Although AAHs have long been recalcitrant to molecular
analysis owing to their small size, the refinement of
microdissection techniques coupled with improvements in
PCR amplification has made it possible to study them at
the molecular genetic level. Initial strategies focused on the
K-ras proto-oncogene as a likely target of mutational activa-
tion, for several reasons: first, activating mutations of K-ras
are detected in 24–50% of lung adenocarcinomas, but
they are much less frequent in other subtypes of lung
cancer [30,31]; second, K-ras mutations are easy to detect
because they involve straightforward base substitutions
that predictably target codon 12 [30]; and third, models of
lung tumorigenesis addressing the chronological sequence
of mutational events predict that K-ras activation is an early
event that precedes malignant growth [32–34].
As expected for an early glandular neoplasm of the lung,
AAHs were found to harbor activating mutations at codon
12 of the K-ras oncogene [14••,35]. Furthermore, the
mutational profile of these K-ras alterations clearly points
to a relationship between AAHs and their fully malignant
counterpart. We found that the frequencies of codon 12
K-ras mutations in AAHs and lung adenocarcinomas are
comparable (39% and 41%, respectively), and the pre-
dominant type of mutation is a G®T transversion at posi-
tion 1 or 2 for both AAH and lung adenocarcinomas
[14••]. The clonal nature of AAH has since been directly
confirmed by X chromosome inactivation analysis. In their
evaluation of AAHs from female patients, Niho et al [36•]
found that all 10 informative cases of AAH were mono-
clonal. The finding that AAH is a clonal proliferation of
cells that harbor activating mutations of a well-recognized
oncogene clearly points to its neoplastic nature.
When AAHs and their synchronous lung carcinomas are
compared for patterns of base substitutions at codon 12
of the K-ras oncogene, the paired lesions often do not
share the same base changes [14••]. Indeed, the pattern
of base changes can be conspicuously divergent for any
individual patient. The discordant nature of these base
changes suggests that AAHs arising in patients with
primary lung carcinomas are independent lesions. They do
not reflect direct extension from a nearby carcinoma or
metastatic implantation from a non-contiguous carcinoma.
With confirmation of AAH as an early stage in glandular
neoplasia, the timing and sequence of specific genetic
alterations now can be delineated along the entire
pathway of lung tumorigenesis. In an effort to separate
early from late mutational events, AAH has been evaluated
for key genetic alterations that are commonly present in
lung adenocarcinomas, including loss of heterozygosity
(LOH) at selected chromosomal arms, alterations of the
p53 tumor suppressor gene, and activation of telomerase.
LOHs on chromosomes 3p, 9p and 17p are common in
adenocarcinomas of the lung [37,38] and are believed to
point to the inactivation of certain tumor suppressor genes
that are critical in lung tumorigenesis. In lung cancer, LOH
at 3p, 9p and 17p probably targets the fragile histidine
triad gene (i.e. FHIT), the p16 gene (i.e. MTS1), and the
p53 gene, respectively. Deletions on chromosomal arms
3p, 9p and 17p are believed to occur during the earliest
stages of lung tumorigenesis, largely on the basis of the
observation that these alterations might be widespread
throughout the lungs of smokers, even in the absence of
overt histopathologic changes in epithelial dysplasia
[39,40]. Not surprisingly, then, LOH of these chromoso-
mal arms has been identified in early as well as advancedstages of glandular neoplasia [24,41,42•]. Among the 20
AAHs that Kitaguchi et al evaluated [24], LOH was
present at 3p (18%), 9p (13%) and 17p (6%).
Mutational inactivation of the p53 tumor suppressor gene
is a frequent genetic event in lung cancer. About half of all
non-small cell lung cancers harbor mutations of the p53
gene [43]. However, alteration of the p53 tumor suppres-
sor gene is probably not a common event in the earliest
stages of glandular neoplasia. Using immunohistochemical
detection of p53 protein accumulation as an indirect mea-
surement of p53 gene alterations, we observed p53
protein accumulation in only 11% of AAHs [27•], a fre-
quency within the range of 8–17% reported by Kitamura
et al [19•,25••]. Moreover, immunohistochemical staining
of p53 often overestimates the true frequency of actual
mutations in the p53 gene [44]. Of four AAHs demonstrat-
ing high levels of p53 protein accumulation, we were able
to document a mutation in the p53 gene by DNA
sequence analysis in only one of these cases [27•].
Telomerase activity is required for the perpetuation of
cancer cells. Activation of telomerase is universally
present in malignant tumors including lung adenocarcino-
mas. In contrast to these fully malignant neoplasms, telo-
merase activity was not detected in any of the six AAHs
evaluated by Yashima et al [45•].
Genetic progression model for glandular
neoplasia of the lung
The concept that AAH constitutes a lone step in early
lung tumorigenesis might be too limited. Instead, AAH
might encompass a heterogeneous population of lesions
representing different points along the progression
toward overt lung adenocarcinoma [25••]. Under the light
microscope, the cytological and architectural atypia that
characterize AAH falls along a morphologic spectrum
ranging from mild to severe. Accordingly, some groups
have attempted to subclassify AAH based on the severity
of this atypia. In addition to low-grade and high-grade cat-
egories of AAH, some schemes also recognize a border-
line lesion that, on morphological grounds, seems to be in
transition from high-grade AAH to early bronchioloalveo-
lar carcinoma (Fig. 3) [19•,25••,46]. These distinct histo-
logic stages might be driven by sequential genetic
events. Activating mutations of the K-ras oncogene tend
to be uniformly distributed across all histopathologic
grades of AAH [27•]. In contrast, LOHs at 3p, 9p and
17p tend to be restricted to AAHs with moderate or
severe cytologic atypia [24]. The frequency of p53
protein accumulation also increases in proportion to the
severity of atypia [19•,25••,27•,28]. We noted that p53
protein accumulation is generally not observed in AAHs
with low-grade morphologic features, but high-level p53
protein accumulation is present in half of those lesions
with severe atypia [27•].
Consistent with the current model of tumorigenesis is the
observation that the development of AAH and its progres-
sion to lung adenocarcinoma depends on the sequential
accumulation of specific genetic alterations (Fig. 4). Acti-
vation of mutations of the K-ras oncogene seems to be an
initiating event. Progression to increasing degrees of mor-
phologic dysplasia might require the silencing of key
tumor suppressor genes such as p16 and FHIT. Ulti-
mately, the inactivation of p53 coupled with the activation
of telomerase might participate in the critical transition
from premalignant to a malignant growth. Further unravel-
ing of these sequential genetic alterations should facilitate
rationale strategies for more effective tumor detection and
surveillance. Molecular analysis of exfoliated cells is now
feasible in the detection of clinically silent neoplasms.
K-ras mutations [47••,48], p53 gene mutations [47••,48],
telomerase activity [49], and alterations of microsatellite
markers [48,50••] have all been idenitified in sputums and
lavages from patients with cancers of the respiratory tract.
Clinical significance of AAH
Although the neoplastic nature of AAH has been con-
firmed at the molecular genetic level, the frequency and
pace of its clinical progression to overt malignancy are
largely unknown. AAH tends to be a multifocal process
such that the finding of AAH in a resection specimen
strongly indicates the presence of other unresected
AAHs. Potentially, these could serve as a source of cancer
relapse. However, for patients who undergo the surgical
Respiratory Research    Vol 1 No 3 Westra
Figure 3
Histologic progression of atypical adenomatous hyperplasia (AAH). (A)
Low-grade AAH characterized by small atypical cells lining a delicate
interstitium. (B) In this high-grade AAH the cells are more crowded,
and there is increased thickening of the septal walls. (C) This lesion
demonstrates morphologic transition between high-grade AAH and an
early bronchioloalveolar carcinoma. It is characterized by further
cellular crowding, increased cytologic atypia and more prominent
fibrosis of the septal walls. (D) In contrast to AAH, this well-
differentiated adenocarcinoma shows severe cytologic atypia and overt
infiltration of the lung parenchyma.removal of low-stage lung cancer, the presence of AAH
does not unfavorably affect prognosis [13,16,51•]. Indeed,
Takigawa  et al [13] identified concurrent AAH in lungs
resected for low-stage adenocarcinomas as a favorable
prognostic indicator. Although much remains to be
learned of the natural history of AAH, its presence does
not necessarily indicate sure and unremitting progression
to an overtly malignant adenocarcinoma.
Continuing technological improvements now permit the pre-
operative identification of AAH with high-resolution imaging
techniques (that is, high-resolution spiral computed tomog-
raphy). These non-invasive techniques permit the longitudi-
nal observation of AAH and thus provide valuable insight
into its natural history. The Early Lung Cancer Action Project
found that out of 99 small (that is, 1–5mm) lung nodules
detected by repeat computed tomography screening in
patients at high risk for lung cancer, only one nodule (1%)
enlarged during follow-up and was ultimately confirmed as a
lung cancer [52]. At present, the presence of AAH does not
merit aggressive surgical intervention. Instead, the detection
of AAH in a patient at risk for lung cancer should initiate
close follow-up, mandate the cessation of smoking, and
prompt consideration of chemopreventive therapy.
Concluding remarks
Most patients with lung cancer are first diagnosed when
their tumors are already clinically and biologically
advanced. For a long time the early non-invasive stages of
glandular neoplasia eluded recognition. Recently, various
lines of evidence have converged to identify AAH as a
non-invasive precursor lesion from which fully malignant
adenocarcinomas arise. Admittedly, AAH is a microscopic
lesion that is incidentally noted in lungs resected for
primary lung cancer. Given its small size, it is virtually invis-
ible to conventional methods of screening for early asymp-
totic lung cancer. Nevertheless, unraveling the molecular
genetic alterations that initiate the development and drive
the progression of these lesions might provide new insight
into the biology of lung cancer, and might facilitate the
design of novel strategies for early detection of lung
cancer. The natural history of AAH, namely the frequency
and pace of its progression to an overtly malignant carci-
noma, is a focus of continuing and future investigations.
http://respiratory-research.com/content/1/3/163
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Figure 4
Progression model for glandular neoplasia of the lung. The clinical (row 1) and histologic (row 2) progression of glandular neoplasia is driven at the
genetic level (row 3) by the accumulation of specific alterations of oncogenes and tumor suppressor genes. These genetic alterations tend to
follow a consistent, but not invariable, chronological order. LOH, loss of heterozygosity.The refinement of high-resolution imaging should help to
clarify this critical unresolved issue.
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